VANCOUVER, British Columbia — November 18, 2025 — Leads & Copy — Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO0), a biopharmaceutical firm utilizing AI for cancer therapy development, has announced that its President and Chief Scientific Officer, Prof. Mads Daugaard, will present and participate as a panelist at the 9th Annual DNA Damage Response (DDR) Inhibitors Summit in Boston, MA, from January 27–29, 2026.
The DDR Inhibitors Summit is a global forum for translational scientists, clinicians, and biotechnology innovators focused on advancing next-generation DDR-targeted cancer therapies. The 2026 program will feature discussions on synthetic lethality, emerging DDR drug targets, biomarkers, and AI-driven discovery, emphasizing translational strategies for clinical impact.
Prof. Daugaard’s presentation is titled “Harnessing AI-Driven Drug Discovery to Accelerate Next-Generation DDR Therapeutics.” He will highlight Rakovina’s shift to an AI-enabled drug discovery model and present studies of AI-designed DDR programs advancing through preclinical lead selection toward development.
In addition to his presentation, Prof. Daugaard will participate in a fireside chat called “Empowering Academic Entrepreneurs to Translate DDR Discoveries Into Impactful Biotech Ventures” and a panel discussion on “Uniting Founders and Funders to Align Scientific Vision with Investment Strategy.” He will join oncology leaders to discuss DDR biology, resistance mechanisms, and clinical strategies.
Prof. Daugaard said the DDR field is undergoing a shift with new discoveries in DNA damage response biology, combination strategies, and AI integration into early discovery. He added that Rakovina is excited to contribute to the scientific dialogue shaping the future of targeted oncology and to share how AI can accelerate the development of precisely engineered DDR therapeutics designed for clinical impact.
Prof. Daugaard, a co-founder of Rakovina and an Associate Professor at the University of British Columbia, brings expertise in cancer biology and therapeutic resistance. His research focuses on uncovering vulnerabilities in tumor survival pathways and advancing them toward targeted drug discovery. His participation in the summit highlights the momentum behind Rakovina’s AI-accelerated DDR pipeline and the company’s role in delivering new therapeutic options for patients with difficult-to-treat cancers.
Rakovina Therapeutics Inc. is a biopharmaceutical research company focused on developing innovative cancer treatments. The company’s work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the Deep-Docking™ and Enki™ platforms. By using AI, Rakovina can review and optimize drug candidates faster than before.
The company has a pipeline of DNA-damage response inhibitors and plans to advance drug candidates into human clinical trials in collaboration with pharmaceutical partners. More information is available at www.rakovinatherapeutics.com.
Michelle Seltenrich, BSc MBA
Director, Corporate Development
IR@rakovinatherapeutics.com
778-773-5432
Source: Rakovina Therapeutics Inc.
